Recent News Releases


Aug 26, 2009
Genmab Announces Positive Top-Line Results for Arzerra™ in Front Line NHL
Aug 18, 2009
Genmab Announces 2009 First Half Year Results
Aug 17, 2009
Genmab Revises Financial Guidance
Aug 17, 2009
GlaxoSmithKline and Genmab Announce Results from a Study of Arzerra in Rituximab Refractory Follicular NHL
Aug 11, 2009
Genmab Announces Preliminary Top-Line Results for Arzerra™ in Front Line CLL
Jul 29, 2009
GlaxoSmithKline and Genmab Announce Top-Line Results for Ofatumumab in Rheumatoid Arthritis
Jul 24, 2009
Recruitment Completed in Arzerra™ (ofatumumab) Phase II Study in Relapsed DLBCL
Jul 16, 2009
Genmab Announces Lift of Zalutumumab Partial Clinical Hold
Jul 9, 2009
Recruitment Completed in Arzerra™ (Ofatumumab) Pivotal CLL Study
Jun 30, 2009
Genmab’s Total Number of Voting Rights and Total Share Capital
Jun 18, 2009
Grant of Warrants to Board Members, Management and Employees in Genmab A/S
Jun 16, 2009
FDA Extends Review of ARZERRA (Ofatumumab)
Jun 10, 2009
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Jun 10, 2009
Recruitment Completed in Zalutumumab Head and Neck Cancer Pivotal Study
Jun 3, 2009
Genmab Announces Partial Clinical Hold on Zalutumumab Studies
Jun 3, 2009
Genmab to Present at Three June Investor Conferences
May 29, 2009
FDA Advisory Panel Makes Favorable Recommendation for GlaxoSmithKline and Genmab’s Arzerra(TM) (Ofatumumab)
May 12, 2009
Genmab Announces 2009 First Quarter Results
May 11, 2009
Ofatumumab and R1507 Data to be Presented at ASCO
May 11, 2009
Genmab to Attend Merrill Lynch Conference
May 4, 2009
FDA Advisory Committee to Review Arzerra™ (Ofatumumab)
Apr 15, 2009
Constitution of the Board of Directors in Genmab and Grant of Warrants to Employees
Apr 15, 2009
Passing of Genmab A/S’ Annual General Meeting
Apr 3, 2009
Arzerra™ (ofatumumab) Granted Priority Review by FDA
Mar 31, 2009
Genmab’s Total Number of Voting Rights and Total Share Capital
Mar 25, 2009
Genmab A/S Summons Annual General Meeting
Mar 23, 2009
Genmab to Attend Kempen & Co Life Sciences Conference 2009
Mar 4, 2009
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Feb 26, 2009
Arzerra™ (ofatumumab) MAA Accepted by EMEA
Feb 26, 2009
Genmab to Attend Two March Investor Conferences
Feb 24, 2009
Genmab Announces Year End 2008 Financial Results
Feb 5, 2009
GlaxoSmithKline and Genmab Seek European Marketing Authorisation of Arzerra (Ofatumumab) in Advanced Stage Blood Cancer
Feb 5, 2009
Major Shareholder Announcement
Jan 30, 2009
GlaxoSmithKline and Genmab Submit Arzerra(TM) (Ofatumumab) Application to FDA for the Treatment of Advanced Stage Blood Cancer
Jan 8, 2009
Genmab to Present at 27th Annual JPMorgan Healthcare Conference
Jan 5, 2009
Genmab Announces Interim Results in Pivotal Study of Zalutumumab in Head and Neck Cancer